FDA Revisits Regulatory Approach to Botanical Drug Products
Source Summary
The FDA is reconsidering its regulatory framework for botanical drugs. The article also covers Ionis Pharmaceuticals' first approval for Alexander disease treatment and discusses barriers facing a leading schizophrenia treatment.
Why it matters
FDA regulatory changes for botanical drugs could affect how plant-based pharmaceutical products are developed and approved, while Ionis' approval represents progress in rare disease treatment.
